We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CRDL market cap is 233.31M. The company's latest EPS is CAD -0.4304 and P/E is -8.29.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 7k | 79k | 0 | 0 |
| Operating Income | -14.13M | -20.68M | -38.66M | -41.34M | -29.79M |
| Net Income | -13.68M | -20.64M | -31.64M | -30.93M | -28.13M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 15.5M | 15.89M | 87.88M | 62.03M | 36.7M |
| Total Liabilities | 831k | 2.62M | 11.64M | 9.83M | 8.45M |
| Total Equity | 14.67M | 13.27M | 76.24M | 52.2M | 28.25M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -11.38M | -9.19M | -23.55M | -27.22M | -25.18M |
| Investing | -424k | -41k | -13k | -75k | -64k |
| Financing | 2.03M | 16.3M | 93.44M | -54k | -55k |
| Market Cap | 233.31M |
| Price to Earnings Ratio | -8.29 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 6.68 |
| Price to Book Ratio | 8.26 |
| Dividend Yield | - |
| Shares Outstanding | 65.35M |
| Average Volume (1 week) | 115.83k |
| Average Volume (1 Month) | 136.67k |
| 52 Week Change | 279.79% |
| 52 Week High | 3.63 |
| 52 Week Low | 0.89 |
| Spread (Intraday) | 0.02 (0.56%) |
| Company Name | Cardiol Therapeutics Inc |
| Address |
2265 upper middle road east oakville, ontario L6H 0C3 |
| Website | https:// |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
